A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

Cancer Research

Volumn 66, Issue 8, 2006, Pages 3987-3991

  Hunter, Chris ^a   Smith, Raffaella ^a   Cahill, Daniel P ^b   Stephens, Philip ^a   Stevens, Claire ^a   Teague, Jon ^a   Greenman, Chris ^a   Edkins, Sarah ^a   Bignell, Graham ^a   Davies, Helen ^a   O'Meara, Sarah ^a   Parker, Adrian ^a   Avis, Tim ^a   Barthorpe, Syd ^a   Brackenbury, Lisa ^a   Buck, Gemma ^a   Butler, Adam ^a   Clements, Jody ^a   Cole, Jennifer ^a   Dicks, Ed ^a   Forbes, Simon ^a   Gorton, Matthew ^a   Gray, Kristian ^a   Halliday, Kelly ^a   Harrison, Rachel ^a   Hills, Katy ^a   Hinton, Jonathon ^a   Jenkinson, Andy ^a   Jones, David ^a   Kosmidou, Vivienne ^a   Laman, Ross ^a   Lugg, Richard ^a   Menzies, Andrew ^a   Perry, Janet ^a   Petty, Robert ^a   Raine, Keiran ^a   Richardson, David ^a   Shepherd, Rebecca ^a   Small, Alexandra ^a   Solomon, Helen ^a   Tofts, Calli ^a   Varian, Jennifer ^a   West, Sofie ^a   Widaa, Sara ^a   Yates, Andy ^a   Easton, Douglas F ^c   Riggins, Gregory ^d   Roy, Jennifer E ^b   Levine, Kymberly K ^b   Mueller, Wolf ^b   Batchelor, Tracy T ^b   Louis, David N ^b   Stratton, Michael R ^a,e   Futreal, P Andrew ^a   Wooster, Richard ^a   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; GENOMIC DNA; PROTEIN KINASE; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GLIOMA; HUMAN; IN VIVO STUDY; MALE; MISMATCH REPAIR; MUTAGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECURRENT CANCER; SOMATIC MUTATION; TUMOR CELL; TUMOR GROWTH;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA-BINDING PROTEINS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASES;

EID: 33646256145     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0127     Document Type: Article

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352: 987-96.
2. Lonardi S, Tosoni A, Brandes AA. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 2005;31:79-89.
3. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005;37:590-2.
4. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5.
5. Bignell G, Smith R, Hunter C, et al. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumours of adolescents and adults. Genes Chromosomes Cancer 2006;45:42-6.
6. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
7. Hegi ME, Diserens A-C, Gorlia T, et al. Mgmt gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
8. Bignell GR, Huang J, Greshock J, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 2004;14:287-95.
9. Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005;102: 14344-9.
10. 1-phase progression. Genes Dev 1999;13:1501-12.
11. Collins V. Amplified genes in human gliomas. Semin Cancer Biol 1993;4:27-32.
12. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003;85:1149-60.
13. Menko FH, Kaspers GL, Meijer GA, et al. A homozygous msh6 mutation in a child with cafe-aulait spots, oligodendroglioma and rectal cancer. Fam Cancer 2004;3:123-7.
14. Hegde MR, Chong B, Blazo ME, et al. A homozygous mutation in msh6 causes Turcot syndrome. Clin Cancer Res 2005;11:4689-93.
15. Mark S, Sandercock L, Luchman H, et al. Elevated mutant frequencies and predominance of g:C to a:T transition mutations 6 (-/-) small intestinal epithelium. Oncogene 2002;21:7126-30.
16. Andrew SE, McKinnon M, Cheng BS, et al. Tissues of msh2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc Natl Acad Sci U S A 1998;95:1126-30.
17. Ohzeki S, Tachibana A, Tatsumi K, Kato T. Spectra of spontaneous mutations at the hprt locus in colorectal carcinoma cell lines defective in mismatch repair. Carcinogenesis 1997;18:1127-33.
18. Tomita-Mitchell A, Kat AG, Marcelino LA, et al. Mismatch repair deficient human cells: spontaneous and MNNG-induced mutational spectra in the hprt gene. Mutat Res 2000;450:125-38.
19. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999;96: 10764-9.
20. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004;64:3391-4.
21. Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.